Jade Biosciences Inc (JBIO) Straddle

Trading a JBIO straddle lets you take a pure volatility position on Jade Biosciences Inc without committing to a direction. Jade Biosciences Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate JBIO straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on JBIO profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Jade Biosciences Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the JBIO straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the JBIO straddle is the cleanest expression of that view. Our scanner prices every JBIO straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a JBIO straddle into a catalyst or short a JBIO straddle to harvest decay, the options straddle setups that matter are all in one place.